Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. Issue 4 (10th December 2019)

• Record Type: Journal Article
• Authors: Noureddin, Mazen; Muthiah, Mark D.; Sanyal, Arun J.
• Is Part Of: Endocrinology, diabetes & metabolism. Volume 3:Issue 4(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-12-10
• Subjects: drug development -- drug therapy -- nonalcoholic steatohepatitis; Endocrinology -- Periodicals; Diabetes -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1002/edm2.105
• Languages: English
• ISSNs: 2398-9238

Abstract

Abstract: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in western populations, and is closely associated with features of the metabolic syndrome. The burden of disease is set to rise exponentially, and this is further compounded by the lack of good medications. In addition, these patients tend to have multiple comorbidities that may not be adequately managed. In this article, we review the biological basis of potential therapies in nonalcoholic steatohepatitis (NASH), the current drugs being tested in clinical trials, as well some practical considerations in managing patients in the clinic. Abstract : In this article, we review the biological basis of potential therapies in NAFLD, the current drugs being tested in clinical trials, as well some practical considerations in managing patients in the clinic.